Chinese Bird Flu Vaccine For Humans Clears Phase II Trials (China)
This article was originally published in PharmAsia News
Executive Summary
Sinovac Biotech said its bird flu vaccine for use in humans has passed Phase II clinical trials without affecting any of the 402 participants. Zhang Jiansan, vice-general manager of the Beijing-based firm, said the test results indicate the vaccine could offer several choices for treatment. The executive also said the nation is capable of producing an appropriate quantity of the vaccine should it be needed. Zhang said the company was able to control the dosage and immunity procedure for the vaccine during the trials, adding to enhanced scientific and effective methods for combating the disease. (Click here for more